SLC12A6: A Potential Drug Target for Various Diseases (G9990)

Target Name: SLC12A6

NCBI ID: G9990

SLC12A6

SLC12A6: A Potential Drug Target for Various Diseases

SLC12A6 is a protein that is expressed in various tissues throughout the body, including the brain, pancreas, and gastrointestinal tract. It is a member of the sulfate transport family 12, which includes proteins that transport sulfates across cell membranes. SLC12A6 is also known as S12A6_HUMAN, and it is a potential drug target or biomarker for various diseases.

The SLC12A6 protein is involved in the transport of sulfates across the blood-brain barrier, which is a barrier that separates the brain from the rest of the body. Sulfates have been shown to play a role in various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia. Therefore, targeting SLC12A6 may be a promising way to develop new treatments for these disorders.

SLC12A6 is also involved in the regulation of insulin secretion from the pancreas. Insulin is a hormone that helps regulate blood sugar levels, and it is produced by the pancreas. SLC12A6 is known to be involved in the regulation of insulin secretion by the pancreas, and alterations in SLC12A6 expression have been observed in various diseases, including type 1 diabetes. Therefore, targeting SLC12A6 may also be a promising way to develop new treatments for type 1 diabetes.

In addition to its role in sulfate transport and insulin regulation, SLC12A6 is also involved in the regulation of inflammation. SLC12A6 has been shown to play a role in the regulation of inflammation in various tissues, including the brain. Therefore, targeting SLC12A6 may be a promising way to develop new treatments for inflammatory disorders.

SLC12A6 is also involved in the regulation of cell signaling pathways. SLC12A6 has been shown to play a role in the regulation of various signaling pathways, including the TGF-β pathway. TGF-β is a signaling pathway that is involved in cell growth, differentiation, and inflammation. Therefore, targeting SLC12A6 may be a promising way to develop new treatments for various signaling pathways that are involved in diseases.

Targeting SLC12A6 may also be a promising way to develop new treatments for various other disorders. For example, SLC12A6 has been shown to be involved in the regulation of cell signaling pathways that are involved in cancer. Therefore, targeting SLC12A6 may be a promising way to develop new treatments for various types of cancer.

In conclusion, SLC12A6 is a protein that is involved in various physiological processes throughout the body. It is a potential drug target or biomarker for various diseases, including Alzheimer's disease, Parkinson's disease, schizophrenia, type 1 diabetes, and various types of cancer. Targeting SLC12A6 may be a promising way to develop new treatments for these disorders. Further research is needed to fully understand the role of SLC12A6 in various diseases and to develop effective treatments.

Protein Name: Solute Carrier Family 12 Member 6

Functions: Mediates electroneutral potassium-chloride cotransport when activated by cell swelling (PubMed:16048901, PubMed:11551954, PubMed:10600773, PubMed:18566107, PubMed:21628467, PubMed:27485015). May contribute to cell volume homeostasis in single cells (Probable) (PubMed:27485015)

The "SLC12A6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC12A6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets